This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The claim about Splitting a weekly dose upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Coming back to post #60, because the follow-up matters more than the original answer.
If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.
This follows post #62 rather than contradicting it.
Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.
It is worth stating the boring hypothesis before the interesting one.
This settles it for me, at least until somebody posts a reason it should not.
I had written a reply contradicting post #64 and deleted it. Here is what survived.
The documentation on Splitting a weekly dose is better than this thread and I say that as someone who has posted in the thread.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
That is a description of practice, not a recommendation of it.
Post #66 is the version of this I will quote in future. One addition.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
I have left out the parts I could not verify.
Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.
Reading it again, the caveat matters more than the finding.
Everything in post #67 holds. The case it does not cover is the one I have.
The version of Splitting a weekly dose that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
A modest claim, modestly supported.
Nothing to add, except that this is the answer I would give if asked.
Post #73 answers the question as asked. The question underneath it is different.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
Filing this under things that are true until someone shows me otherwise.
If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.
Genuinely open to being wrong about this one.
Post #79 is right about the mechanism and I think understates the practical bit.
A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
Building on post #80 rather than restating it.
When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.
Post #78 put the caveat in the right place and I want to underline it.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
I am not the right person to answer the follow-up to this.
Research-use-only material is not a licensed product and no labelling covers it. Everything in this subcategory about published schedules describes what was done in trials of licensed formulations.
The mechanism is plausible, which is not the same as established.
Two questions I would want answered before drawing anything from the Splitting a weekly dose data above: how were the cases selected, and what happened to the ones that dropped out.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
That matches what I have seen, for whatever a single anecdote is worth.
What I want from this Splitting a weekly dose thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.
I am reporting what happened, not recommending it.
Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.
I would put the burden of proof on the interesting explanation, not the dull one.